JW Pharmaceutical Corporation (KRX:001065)
South Korea · Delayed Price · Currency is KRW 26,700
+350 (1.33%)
Mar 20, 2026, 2:00 PM KST
JW Pharmaceutical Cash Flow Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | 61,511 | 65,040 | 37,006 | 31,892 | -967.85 |
Depreciation & Amortization | 18,748 | 19,101 | 22,575 | 16,836 | 16,112 |
Loss (Gain) From Sale of Assets | 46.76 | -464.91 | 1,088 | -3.28 | 1,048 |
Asset Writedown & Restructuring Costs | - | 1,476 | - | 4,821 | - |
Loss (Gain) From Sale of Investments | -1,578 | -790.9 | -2,830 | 8,515 | 1,820 |
Loss (Gain) on Equity Investments | -2,259 | -1,387 | -621.06 | 1,349 | 1,149 |
Provision & Write-off of Bad Debts | -3,216 | -6,081 | -3,644 | 8,437 | 12,073 |
Other Operating Activities | 14,723 | 11,782 | 53,846 | -8,913 | 32,946 |
Change in Accounts Receivable | 24,022 | 29,965 | -4,734 | -4,312 | -41,566 |
Change in Inventory | 340 | -8,775 | 8,917 | -11,541 | -2,655 |
Change in Accounts Payable | -3,512 | -14,527 | -9,536 | 31,652 | 3,730 |
Change in Unearned Revenue | - | - | -153.66 | -53.5 | - |
Change in Other Net Operating Assets | -12,429 | -15,946 | -14,756 | -21,915 | -5,564 |
Operating Cash Flow | 96,396 | 79,392 | 87,157 | 56,764 | 18,124 |
Operating Cash Flow Growth | 21.42% | -8.91% | 53.54% | 213.20% | -71.26% |
Capital Expenditures | -11,772 | -8,313 | -27,286 | -9,919 | -7,467 |
Sale of Property, Plant & Equipment | 45.45 | 46.4 | 24.97 | 6.26 | 63,446 |
Cash Acquisitions | - | -138.7 | -12,005 | -40.88 | - |
Divestitures | - | - | - | - | 384.96 |
Sale (Purchase) of Intangibles | -24,348 | -17,734 | -13,419 | -2,433 | -5,435 |
Investment in Securities | 34,055 | 31,725 | 8,260 | -26,344 | 1,078 |
Other Investing Activities | -4,078 | 358.72 | -6,355 | 267.37 | -44,541 |
Investing Cash Flow | -7,198 | 14,085 | -63,780 | -18,919 | -22,869 |
Short-Term Debt Issued | 56,098 | 104,737 | 227,876 | 110,896 | 75,323 |
Long-Term Debt Issued | - | 25,102 | 60,166 | 29,585 | 60,296 |
Total Debt Issued | 56,098 | 129,839 | 288,042 | 140,481 | 135,619 |
Short-Term Debt Repaid | -80,498 | -171,805 | -316,108 | -177,004 | -84,408 |
Long-Term Debt Repaid | -14,767 | -47,809 | -4,051 | -2,795 | -16,845 |
Total Debt Repaid | -95,265 | -219,613 | -320,159 | -179,799 | -101,254 |
Net Debt Issued (Repaid) | -39,167 | -89,774 | -32,117 | -39,318 | 34,365 |
Issuance of Common Stock | - | - | - | 10,000 | 398.47 |
Repurchase of Common Stock | -9,540 | -750.42 | -260.88 | -281.6 | -412.29 |
Common Dividends Paid | -11,068 | -9,665 | -8,814 | -7,352 | -7,149 |
Other Financing Activities | - | -0 | -54 | 44 | -0 |
Financing Cash Flow | -59,776 | -100,190 | -41,245 | -36,907 | 27,202 |
Foreign Exchange Rate Adjustments | -619.74 | 1,234 | -120.69 | -406.38 | 458.72 |
Net Cash Flow | 28,803 | -5,479 | -17,989 | 531.45 | 22,915 |
Free Cash Flow | 84,625 | 71,079 | 59,871 | 46,845 | 10,657 |
Free Cash Flow Growth | 19.06% | 18.72% | 27.81% | 339.56% | -78.97% |
Free Cash Flow Margin | 10.91% | 9.88% | 8.00% | 6.84% | 1.76% |
Free Cash Flow Per Share | 3486.17 | 2889.49 | 2515.25 | 2016.97 | 459.20 |
Cash Interest Paid | 2,944 | 8,136 | 11,119 | 9,035 | 7,567 |
Cash Income Tax Paid | 29,444 | 16,587 | 13,335 | 31,621 | 863.42 |
Levered Free Cash Flow | 83,592 | 41,864 | 23,381 | 74,265 | -6,672 |
Unlevered Free Cash Flow | 86,357 | 48,135 | 31,232 | 80,132 | -2,087 |
Change in Working Capital | 8,420 | -9,283 | -20,263 | -6,170 | -46,056 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.